2018, Number 3
Synergistic effect of combined IFN-alpha2b and IFN-gamma treatment for periocular basal cell carcinoma
PDF size: 486.73 Kb.
ABSTRACTPurpose: To evaluate the results for the application of the perilesional HerberPAG on periocular basal cell carcinoma. Methods: An experimental investigation was carried out on a group of 7 patients who were given the same treatment regimen with HeberPAG® 10.5 × 106 UI 3 times a week for 3 consecutive weeks. Demographic variables where considered as well as time of evolution, initial injury size, clinical subtype, histological subtype, clinical response, objective response and adverse effects. Results: The average time of evolution of the injury was 7.0 ± 1.6 months, with a higher diameter medium of 17.4 ± 2.3 mm. The clinic nodule-ulcerative subtype was presented on 42.9% of the subjects and the solid and superficial hostiological subtypes were presented with an equal proportion of 42.9%. Conclusions: The use of HerberPAG was effective and could be considered as a useful and a safe alternative as a conservative treatment in subjects with periocular basal cell carcinoma when other therapies are not available.
García Vega Y, García García I, Collazo Caballero SE, Santely- Pravia EE, Cruz-Ramírez A, Tuero-Iglesias AD, et al. Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG®) in patients with mycosis fungoides: an open-label trial. BMC Pharmacol Toxicol. 2012;13:20.